WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Pharmsource, LLC
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Pharma Tech
Cadence | July 26, 2022
Cadence Design Systems, Inc. announced that it has entered into a definitive agreement to acquire privately held OpenEye Scientific Software, Inc., a leading provider of computational molecular modeling and simulation software being widely and increasingly used by pharmaceutical and biotechnology companies for drug discovery. The addition of OpenEye’s technologies and experienced team with its deep scientific expertise accelerates Cadence’s Intelligent System Design&tr...
BioTechniques | April 08, 2020
Providing the latest updates in the understanding of coronavirus, drug development and clinical trials for a vaccine for COVID-19. A study seeking to determine which of the lung and bronchi cells are targets for SARS-CoV-2 has been recently published in The EMBO Journal, suggesting the target is progenitor cells that usually develop into respiratory tract cells lined with cilia. This follows previous research that had demonstrated that the virus spike protein attaches to the ACE2 receptor on cel...
Intec Pharma | October 08, 2020
Intec Pharma Ltd. ("Intec" or "the Company") today announces it has entered into a new research collaboration agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth, NJ, USA. Details of the agreement are confidential. "We are very excited to continue to work with MSD," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "This new agreement builds upon the relationship we have enjoyed in prior research and allows t...
Business Insights
Cellusion and Celregen | September 12, 2022
Cellusion Inc. a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells for bullous keratopathy novel treatment and Hangzhou Celregen Therapeutics Ltd. a member of Shanghai Fosun Pharmaceutical Co., Ltd. and focus on regenerative medicine and cell therapy and incubated by New Drug Fund of Fosun Health Capital announced an exclusive...
Pharmacy Market
Whitepaper
Video
Business Insights, PHARMA TECH
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE